Share this article on:

Abstract 22: Tafluprost, a Prostaglandin F2a Analog, Has Therapeutic Potential for Androgenic Alopecia through Modulation of Hair Cycle

Plastic and Reconstructive Surgery – Global Open: April 2016 - Volume 4 - Issue 4S - p 45
doi: 10.1097/01.GOX.0000488954.39656.77
PRS PSRC Podium Proofs 2016

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Kahori Kinoshita, MD,* Harunosuke Kato, MD,* Hiroko Takada, PhD,† Koji Kanayama, MD,* Takanobu Mashiko, MD,* Kenzo Koike, PhD,‡ Akira Kurisaki, PhD,† Satoshi Itami, MD,§ Kotaro Yoshimura, MD¶

From the *Department of Plastic Surgery, The university of Tokyo, Tokyo, Japan; †Research Center for Stem Cell Engineering, National Institute for Advanced Industrial Science and Technology, Ibaraki, Japan; ‡Beauty Research Center, KAO Corp., Tokyo, Japan; §Department of Regenerative Dermatology, Osaka University, Osaka, Japan; and ¶Department of Plastic Surgery, The university of Tokyo, Jichi Medical University, Tokyo, Tochigi, Japan.

PURPOSE: Topical prostaglandin (PG) F2α was recently reported to promote hair growth, and a new PGF2α analog, tafluprost, was investigated in this study.

METHODS: Topical tafluprost was applied once daily on either telogen skin or depilation-induced anagen skin in C57BL/6 mice using 7 different concentrations, and hair growth was evaluated until day 42. The underlying mechanism was explored by various in vitro and in vivo approaches.

RESULTS: Tafluprost application on telogen skin promoted telogen-to-anagen conversion most at the same concentration as a commercial eye drop. Hair protrusion was observed much earlier (day 19.6 ± 0.7) than control (day 42). In depilation-induced anagen mice, tafluprost elongated early anagen phase, but did not elongate mid-late anagen phase. In organ culture of human scalp hair and mice vibrissa follicles, hair growth was not accelerated by tafluprost, and proliferation of cultured human dermal papilla cells (hDPCs) was not affected by tafluprost in BrdU incorporation analysis. Chick chorioallantoic membrane assay showed no promotion of angiogenesis by tafluprost. Microarray using hDPCs and human keratinocytes (hKCs) showed that interleukin (IL)-1β, known to induce catagen, and inflammatory cytokines such as IL-6, IL-8, and CXCL2 were downregulated in tafluporst-treated hDPCs, whereas hair cycle-associated growth factors such as FGF-1, 2, and 7 were stable. Genes related to keratinization were upregulated in hKCs. The correlation between PGF2α, PGD2, and PGE2 was also evaluated in gene expression using real-time polymerase chain reaction, indicating the affected profile of these genes.

CONCLUSIONS: Tafluprost affected the function of hDPCs and hKCs and showed therapeutic potentials for androgenic alopecia by modulating hair cycle such as anagen induction and elongation of early anagen.

© 2016 American Society of Plastic Surgeons